First line gefitinib monotherapy for brain metastases patients with advanced non-small cell lung cancer
- VernacularTitle:吉非替尼一线治疗并发脑转移非小细胞肺癌观察
- Author:
Zhu WANG
;
Jiandong TONG
;
Xin YUAN
;
Fang HAN
- Publication Type:Journal Article
- Keywords:
Careinoma,non-small cell Lung;
Neoplasm metastasis;
Gefitinib
- From:
Chinese Journal of Primary Medicine and Pharmacy
2008;15(9):1419-1420
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and toxicity of gefitinib on the treatment of advanced NSCLC with brain metastases.Methods 17 cases received gefitinib 250 mg/m2/d,30 days a cycle.Results Objective response rate of 35.3% was achieved,and DCR was 70.6% ,the toxic reactions could be controlled with relative therapy.Conclusion Gefitinib is effective and well tolerable for advanced NSCLC with brain metastases.It is worth to be used.
